68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses a novel radiotracer, 68Ga-YQ-CC05, administered intravenously to participate patients to perform PET-CT scans. The goal is to assess safety and to verify whether the probe can improve tumor visualization in individuals with medullary thyroid carcinoma, small cell lung cancer, or gastric adenocarcinoma. Enrollment is limited to adults aged 18 to 75 who have tumors detectable by imaging and minimal organ function abnormalities. Participants must provide informed consent and meet specified kidney, liver, and blood test criteria. The study is located at Nanjing First Hospital and is led by Nanjing First Hospital, Nanjing Medical University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Volunteer to participate in the trial, with the patient or their legal guardian signing the informed consent form;
* Volunteers are not limited by gender, and the age range is from 18 to 75 years old, inclusive;
* Other imaging examination methods (CT, MRI, etc.) reveal tumor occupying lesions;
* Tumor patients who can obtain the final pathological results.
* Kidney: GFR \> 50 ml/min, ERPF \> 280 ml/min, platelet count (PLT) \> 75,000/μL, white blood cell (WBC) \> 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value.

Exclusion Criteria:

* Individuals with a history of allergy to similar drugs (drugs with similar chemical or biological components to CCK2R), allergic constitution, or current allergic diseases;
* Those who are currently participating in other clinical drug studies, or have previously participated in any clinical drug studies (excluding vitamins and minerals);
* Other uncontrollable clinical issues (such as HIV, hepatitis C virus infection, active hepatitis B, or other severe chronic infections, as well as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases);
* Red blood cells (RBC) count less than 4×10\^12, white blood cells (WBC) count less than 3×10\^9, hemoglobin level less than 110g/L, and platelet count (PLT) less than 75,000×10\^9;
* Obvious abnormalities in liver and kidney function, with GFR less than 50 ml/min;
* Tumor burden greater than 50%, or significant spinal cord compression;
* Expected survival duration less than half a year; chemotherapy within 6 months;
* Having severe acute concomitant diseases or severe treatment-resistant mental disorders;
* Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test result);
* Patients who are physically unfit for radiological examinations;
* Other situations where the researcher deems it inappropriate for the participant to participate in the trial.

Where it's running

• Nanjing First Hospital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Feng Wang
• Email: fengwangcn@hotmail.com
• Phone: +8602552271491

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• Exploration of whole-brain radiotherapy with PD-1 inhibitors for brain injury in SCLC

  This study tests whether adding PD-1 inhibitors to chemotherapy and prophylactic brain irradiation helps some small cell lung cancer patients protect the brain.

  Recruiting Guizhou Medical University · Guiyang, Guizhou · NCT07905937

• Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer

  This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886047

• Neoadjuvant immunotherapy plus Nab-P-SOX for locally advanced gastric/GEJ cancer

  This phase 2, single-arm study tests a pre-surgery treatment that combines a PD-1/CTLA-4 bispecific antibody with nab-paclitaxel, oxaliplatin, and S-1 in adults with HER2-negative, locally advanced gastric or GEJ cancer.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07867392

• IDP-121 plus chemotherapy in platinum-resistant small cell lung cancer

  This trial tests higher and higher doses of IDP-121 with chemotherapy to see if it is safe and workable for adults with advanced small cell lung cancer that progressed after first-line platinum therapy.

  Recruiting at 6 sites Phase 1/2 IDP Discovery Pharma S.L. · Barcelona and 9 other locations · NCT07864207

• Maintenance therapy in metastatic gastric cancer: a multicenter look from Colombia

  This study reviews medical records of adults with metastatic gastric cancer in Colombia to see how patients fare after starting maintenance therapy following initial chemotherapy.

  Recruiting at 4 sites Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. and 3 other locations · NCT07856212

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.